AstraZeneca PLC Valuation
| AZN Stock | 10,568 30.00 0.28% |
At this time, the firm appears to be fairly valued. AstraZeneca PLC shows a prevailing Real Value of USD10507.94 per share. The current price of the firm is USD10568.0. Our model approximates the value of AstraZeneca PLC from analyzing the firm fundamentals such as Current Valuation of 184.21 B, profit margin of 0.13 %, and Return On Equity of 0.17 as well as examining its technical indicators and probability of bankruptcy.
Price Book 5.1273 | Enterprise Value 184.2 B | Enterprise Value Ebitda 15.8333 | Price Sales 3.1996 | Forward PE 14.3885 |
Fairly Valued
Today
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the AstraZeneca stock is determined by what a typical buyer is willing to pay for full or partial control of AstraZeneca PLC. Since AstraZeneca PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AstraZeneca Stock. However, AstraZeneca PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10568.0 | Real 10507.94 | Hype 10572.56 | Naive 9948.62 |
The real value of AstraZeneca Stock, also known as its intrinsic value, is the underlying worth of AstraZeneca PLC Company, which is reflected in its stock price. It is based on AstraZeneca PLC's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of AstraZeneca PLC helps investors to forecast how AstraZeneca stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors: AstraZeneca PLC Cash |
|
AstraZeneca PLC Total Value Analysis
AstraZeneca PLC is presently forecasted to have takeover price of 184.21 B with market capitalization of 163.84 B, debt of 28.62 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the AstraZeneca PLC fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
184.21 B | 163.84 B | 28.62 B |
AstraZeneca PLC Investor Information
About 53.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.73. AstraZeneca PLC last dividend was issued on the 8th of August 2024. Based on the measurements of operating efficiency obtained from AstraZeneca PLC's historical financial statements, AstraZeneca PLC is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 10.9 B | 10.3 B |
|
| |||||
| Operating Income | 5 B | 8.2 B |
|
|
AstraZeneca PLC Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AstraZeneca PLC has an asset utilization ratio of 45.3 percent. This indicates that the Company is making USD0.45 for each dollar of assets. An increasing asset utilization means that AstraZeneca PLC is more efficient with each dollar of assets it utilizes for everyday operations.AstraZeneca PLC Ownership Allocation
AstraZeneca PLC holds a total of 1.55 Billion outstanding shares. Over half of AstraZeneca PLC's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in AstraZeneca PLC. Please watch out for any change in the institutional holdings of AstraZeneca PLC as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.AstraZeneca PLC Profitability Analysis
The company reported the revenue of 45.81 B. Net Income was 6.9 B with profit before overhead, payroll, taxes, and interest of 35.73 B.AstraZeneca PLC Past Distributions to stockholders
| 9th of September 2024 | ||
| 8th of August 2024 | ||
| 25th of March 2024 | ||
| 11th of September 2023 | ||
| 10th of August 2023 | ||
| 27th of March 2023 |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates AstraZeneca PLC's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in AstraZeneca PLC and how it compares across the competition.
About AstraZeneca PLC Valuation
The stock valuation mechanism determines AstraZeneca PLC's current worth on a weekly basis. Our valuation model uses a comparative analysis of AstraZeneca PLC. We calculate exposure to AstraZeneca PLC's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AstraZeneca PLC's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 37.8 B | 19.9 B |
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |